{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-132883","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.799054+00:00","generated_at":"2026-05-29T09:51:09.324643+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Trevi Therapeutics announces positive HAP study results for oral nalbuphine; primary endpoint met at clinical doses","bullets":["Primary endpoint: mean Emax for 'Drug Liking' for oral nalbuphine 81mg was 71.2 vs IV butorphanol 6mg (82.3), p<0.0001.","Oral nalbuphine 162mg also statistically significant (74.5 vs 82.3, p=0.0008); 486mg supratherapeutic dose not significant (p=0.3221).","No serious adverse events reported; secondary endpoints (e.g., 'Take Drug Again,' 'I Feel High') consistent with primary result.","Results will be included in 8-factor abuse potential analysis for nalbuphine ER as part of planned NDA submission."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-132883","json":"https://secwatch.observer/filing/0000950170-24-132883.json","markdown":"https://secwatch.observer/filing/0000950170-24-132883.md","text":"https://secwatch.observer/filing/0000950170-24-132883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024132883/0000950170-24-132883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024132883/trvi-20241203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:51:09.324643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}